Valeant wraps up Salix marketing probe with $54M deal--but it's far from in the clear

Money Handshake

Embattled drugmaker Valeant has one less thing to worry about. The company agreed to pay $54 million to settle federal and state marketing allegations for three drugs it picked up in its Salix Pharmaceuticals buyout, Xifaxan, Relistor and Apriso, according to a Tuesday securities filing.

Of course, Valeant isn’t totally in the clear when it comes to Salix, which it nabbed last spring for $11 billion after winning a bidding war with Endo. Before Salix put itself up for sale, it revealed a wholesaler pile-up that forced it to restate earnings and bid farewell to its CFO (with its CEO retiring shortly thereafter). And the SEC is still conducting a formal probe into possible securities law violations relating to those inventory disclosures, Valeant said. Shareholders also filed three class-action lawsuits in late 2014.

On top of that, Xifaxan--the GI drug Valeant was most eager to get its hands on with the acquisition--hasn’t been living up to expectations. On Tuesday’s Q1 conference call, new CEO Joseph Papa cited sales force turnover, shifts in strategy, changes in leadership and an increase in enrollment in high-deductible healthcare plans as factors forcing the Canadian drugmaker to lop $390 million off its 2016 sales predictions for the med.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Still, Valeant and Papa must be happy to get one item off their plates as they grapple with a host of other issues, including multiple investigations, a Walgreens drug-distribution pact that’s hurting key dermatology sales, a stock price in the doldrums, a debt pileup, and a well of investor confidence that’s nearly run dry.

“Negative external attention … continues to adversely impact the business and our reputation with patients, physicians, and all of you, our shareholders, as well as our distracted organization,” Papa said on the call.

- see Valeant's 10-Q
- read the conference call transcript

Special Report: The most influential people in biopharma today - 2016 - J. Michael Pearson - Valeant

Related Articles:
Desperation drove Valeant to a sub-par Walgreens deal, and now it wants to renegotiate​
Valeant’s image may have hit a new low after Tuesday’s Q1 call
Valeant slashes guidance yet again as Q1 earnings take a beating
After topping Q1 estimates, Valeant hikes guidance on Salix buy
Departed Salix execs score $47M with Valeant buyout
Sorry, Endo. Valeant's back on top with $173-per-share Salix bid
With Salix buy, Valeant bets $10B on GI market growth
Looking to get out of the hot seat, Salix to restate financials for past 7 quarters

Suggested Articles

Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.